Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
381-400 of 3,900 trials

HPV Vaccination Timing After Stem Cell Transplant

We are comparing early versus late vaccination with Gardasil 9® in patients who have had a stem cell transplant. The goal is to see which timing produces a stronger immune response against HPV.

Recipients of Allogeneic Stem Cell TransplantationEfficacy phase (II)No PlaceboStandard MedicinesHematologyInfectious DiseasesOncology

Eptinezumab for Migraines in Children and Adolescents

We are studying the long-term safety of eptinezumab in children and teens aged 6 to 17 who experience chronic or episodic migraines. This research aims to ensure the medication is safe for young patients.

Migraine6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

PARP-PET Imaging in Solid Tumors

We are exploring how PARP-PET imaging can help in diagnosing and monitoring solid tumors. This study aims to see if it provides better insights compared to standard imaging methods.

Castration-Resistant Prostate CancerMetastatic Breast CancerMetastatic Ovarian Cancer>2 yearsSafety phase (I)Oncology

HIV Prevention: TAF/FTC Medication

We are testing a new event-driven medication for HIV prevention in men who have sex with men in Thailand and France. The study aims to assess its effectiveness, safety, and how well participants accept it.

HIV Prevention>2 yearsConfirmation phase (III)Infectious Diseases

Fronto-Temporal Dementia: LY3884963 Treatment Study

We are testing a new injection for patients with fronto-temporal dementia due to progranulin mutations. The study aims to evaluate its safety and effects on a key protein related to the disease.

Frontotemporal Dementia>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Partial Lipodystrophy: Metreleptin Treatment Study

We are studying the daily use of metreleptin in patients with partial lipodystrophy to see if it improves their condition and related health factors. This includes looking at liver health and insulin sensitivity over time.

Partial Lipodystrophy>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteEndocrinologyInternal Medicine

Idiopathic Pulmonary Fibrosis: Axatilimab Study

We are testing a new medication, axatilimab, for people with idiopathic pulmonary fibrosis to see if it improves lung function and overall quality of life compared to a placebo.

Idiopathic Pulmonary Fibrosis6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Prostate Cancer: AAA617 Treatment Study

We are studying a new drug, AAA617, for adult men with oligometastatic prostate cancer to see if it can delay disease progression compared to standard observation. This trial aims to evaluate its effects on survival and quality of life.

Oligometastatic Prostate Cancer3-6 monthsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Lung Cancer Treatment: DZD9008 vs. Chemotherapy

We are studying a new medication, DZD9008, for patients with advanced non-small cell lung cancer that has a specific genetic mutation. The goal is to see if it works better than standard chemotherapy.

Advanced Non-Small Cell Lung Cancer with EGFR MutationConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncologyPulmonology

Severe Infections: MODIFY Trial

We are testing a new method to guide antibiotic treatment for severe infections, aiming to reduce unnecessary antibiotic use. This study will also evaluate how this approach impacts recovery and health outcomes.

Sepsis>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Atypical Hemolytic Uremic Syndrome: Long-Term Study of Iptacopan

We are evaluating the long-term safety and effects of iptacopan in individuals with atypical hemolytic uremic syndrome. This study looks at how well the treatment works in preventing complications and improving kidney health.

Atypical Hemolytic Uremic Syndrome>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNephrology

Filgotinib for Rare Immune Diseases

We are studying how filgotinib may improve quality of life and disease activity in patients with rare conditions like Behçet's disease, idiopathic inflammatory myopathy, and IgG4-related disease.

DermatomyositisAntisynthetase SyndromeIgG4-Related Disease6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesRheumatology

Clostridioides difficile Infection: VE303 Treatment Study

We are testing a new treatment, VE303, to see if it helps prevent recurrent Clostridioides difficile infections in people who have had this infection before. The study will also evaluate safety and quality of life for participants.

Clostridioides difficile Infection6-12 monthsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInfectious Diseases

Cutibacterium acnes Infections: Rifampicin Study

We are investigating whether rifampicin is safe and effective for treating prosthetic joint infections caused by Cutibacterium acnes. This study compares rifampicin with other antibiotic treatments to see which works better.

Joint Infection from Medical Devices>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesOrthopedics and Traumatology

Metastatic Leiomyosarcoma: Lurbinectedin and Doxorubicin Study

We are investigating whether combining lurbinectedin with doxorubicin helps patients with metastatic leiomyosarcoma live longer without disease progression compared to doxorubicin alone. This study aims to improve treatment options for this rare cancer.

Metastatic Leiomyosarcoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Advanced Breast Cancer: Giredestrant vs. Fulvestrant

We are studying a new medication, giredestrant, to see if it works better than fulvestrant for patients with advanced breast cancer who have not responded to prior hormone therapy. The trial will also evaluate the safety of both treatments.

Estrogen Receptor Positive, HER2 Negative Advanced Breast Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

ZN-c3 for High-Grade Serous Ovarian Cancer

We are studying a new treatment called azenosertib for individuals with high-grade serous ovarian cancer. The trial aims to evaluate its safety and effectiveness, especially in patients with a specific genetic marker.

Ovarian, Fallopian Tube, and Peritoneal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Atrial Fibrillation: Stopping Anticoagulants After Heart Surgery

We are studying whether patients with atrial fibrillation can safely stop anticoagulant therapy after undergoing surgical left atrial appendage closure. This trial looks at the risks of stroke and bleeding in these patients.

Atrial Fibrillation>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementCardiologyInternal Medicine

Rheumatoid Arthritis: LY3871801 Study

We are testing a new medication, LY3871801, for adults with moderately-to-severely active rheumatoid arthritis. The study aims to see if it can reduce disease activity better than a placebo.

Rheumatoid Arthritis3-6 monthsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Vericiguat for Vasospastic Angina

We are studying how vericiguat affects heart function and angina episodes in patients with vasospastic angina. The trial also looks at quality of life and safety of the treatment.

Vasospastic Angina1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteCardiologyInternal Medicine